Sign in

You're signed outSign in or to get full access.

RB

Regen BioPharma Inc (RGBP)·Q4 2024 Earnings Summary

Executive Summary

  • Regen BioPharma reported FY Q4 2024 (quarter ended Sept 30) license-driven revenue of approximately $59.37K, bringing FY revenue to $236.56K; Q4 net loss was ~$264.9K, widening sequentially due to higher other expenses versus stable operating loss trajectory .
  • No Wall Street consensus from S&P Global was retrievable for this microcap during this session; as a result, beats/misses versus estimates are unavailable for this recap (consensus unavailable via S&P Global).
  • Liquidity remains tight: quarter-end cash was $715 and current liabilities were $5.37M, highlighting reliance on external financing (equity line and notes); going-concern uncertainty persists .
  • Strategic update: management reiterated plan to initiate the FDA-cleared HemaXellerate Phase 1 (aplastic anemia), with a 12–14 month completion timeline post-initiation—an important stock narrative catalyst tied to clinical execution .

What Went Well and What Went Wrong

  • What Went Well

    • Revenue consistency: quarterly revenue held around ~$59K throughout FY24, reflecting recurring license economics from Oncology Pharma and related-party Zander agreements .
    • Operating discipline: Q4 operating loss ($86K) improved vs Q2/Q3 ($101K/~$108K), pointing to some OpEx control in the period .
    • Clinical pathway: “With FDA clearance to begin clinical trials, HemaXellerate™ has the potential to redefine the treatment landscape,” noted CEO Dr. Koos, framing a tangible near-term program with potential orphan pathway advantages and CRO partnership in place .

  • What Went Wrong

    • Balance sheet strain: Q4 cash of $715 vs current liabilities of $5.37M underlines funding risk and going-concern uncertainty; derivative liabilities and notes payable remain material .
    • Other expense drag: FY saw sizable negative other items (interest and unrealized losses), contributing to a full-year net loss of $867K despite modest operating losses .
    • No earnings call and limited external coverage: absence of a Q4 earnings call and (in this session) no accessible S&P Global consensus limits near-term institutional engagement and visibility (consensus unavailable via S&P Global).

Financial Results

MetricQ2 2024Q3 2024Q4 2024FY 2024
Revenue ($USD)$59,065 $59,065 $59,366 (calc = FY − 9M) $236,560
Operating Income (Loss) ($USD)$(101,071) $(107,966) $(86,370) (calc) $(418,189)
Net Income (Loss) ($USD)$(122,473) $(130,120) $(264,899) (calc = FY − 9M) $(867,252)
EPS ($)$(0.03) $(0.03) N/A (not disclosed)$(0.21)
Net Income Margin (%)−207.3% (calc) −220.3% (calc) −446.0% (calc) −366.7% (calc)

Notes:

  • Q4 revenue and Q4 net loss are computed from disclosed FY and 9M data; quarterly EPS for Q4 is not disclosed and cannot be reliably derived due to differing weighted-average shares .

Segment/Revenue composition (license-driven)

Revenue CompositionQ2 2024Q3 2024FY 2024
Third-Party Licensing ($USD)$31,640 $31,640 $126,560
Related-Party Licensing ($USD)$27,425 $27,425 $110,000
Total ($USD)$59,065 $59,065 $236,560

KPIs and balance sheet snapshots

KPI (End of Period)Q2 2024Q3 2024Q4 2024
Cash and Equivalents ($USD)$78,114 $61,849 $715
Unearned Income (Deferred Revenue) ($USD)$1,528,451 $1,496,811 $1,465,171
Derivative Liability ($USD)$1,400,000 $1,400,261 $1,397,274
Notes Payable (Current) ($USD)$49,210 $218,230 $293,819
Convertible Notes Payable (Current, net of discount) ($USD)$499,880 $499,880 $499,880
Common Shares Outstanding (End of Period)4,114,622 4,373,078 5,258,235

Guidance Changes

MetricPeriodPrevious GuidanceCurrent GuidanceChange
Financial Guidance (Revenue, Margin, EPS)FY/Q4 2024NoneNoneN/A (no guidance provided)
HemaXellerate Phase 1 TimelinePhase 1Not previously specifiedExpected completion 12–14 months after initiationInitial timeline disclosed

Earnings Call Themes & Trends

No Q4 2024 earnings call or transcript was found.

TopicPrevious Mentions (Q2, Q3 FY24)Current Period (Q4 FY24)Trend
Clinical execution (HemaXellerate)Focus on preclinical and license model; no quarter-specific trial timeline disclosed FDA-cleared Phase 1; 12–14 month completion once initiated; CRO engaged Improving visibility on execution
Financing/liquidityEquity line with Coventry; small cash balance; notes outstanding Cash $715; added $250K Coventry note in Sept; continued going-concern risk Funding pressure persists
Revenue modelLicensing with Oncology Pharma and Zander; ~$59K quarterly cadence FY total $236.56K; similar cadence implied Stable but small scale
Related-party exposureZander license and receivables; governance disclosures Continued related-party notes and license economics Ongoing
Derivative/convertible overhangMaterial derivative liabilities and convertibles Slightly lower derivative liability; convertibles unchanged Neutral to modestly better

Management Commentary

  • “With FDA clearance to begin clinical trials, HemaXellerate™ has the potential to redefine the treatment landscape—not just for aplastic anemia but for a wide range of hematological disorders.” — Dr. David Koos, Chairman & CEO .
  • Management reiterates going concern risks and dependence on external financing to meet obligations and pursue strategy .

Q&A Highlights

  • No Q4 FY24 earnings call or Q&A was published (no transcript found).

Estimates Context

  • We attempted to retrieve S&P Global consensus for Q4 and FY24; estimates were not retrievable in this session, so comparisons to consensus are unavailable in this recap. Where estimates are needed, treat consensus as unavailable (S&P Global consensus unavailable in session).

Key Takeaways for Investors

  • Cash runway is extremely tight (cash $715 at Q4-end) with sizeable current liabilities, derivative liabilities, and notes payable; near-term financing actions are a key stock driver .
  • Revenue remains small and steady (~$59K per quarter) from licensing; any new/out-licensing or progress payments are potential upside catalysts but not yet evident in results .
  • Initiation and execution of the FDA-cleared HemaXellerate Phase 1 could shift the narrative toward clinical milestones; watch for site activation, first-patient-in, and update cadence (12–14 months completion post-initiation) .
  • Capital structure overhang (convertibles, derivative liabilities) and related-party dynamics persist; monitoring covenant/status of the Coventry facilities and note amortizations is essential .
  • Without guidance and no accessible consensus this period, trading is likely to hinge on financing headlines and clinical trial start/operational updates rather than earnings metrics (consensus unavailable via S&P Global).

Sources

  • 8-K including Item 2.02 and Exhibit 99.1 (Unaudited financials for FY ended 9/30/2024) .
  • Q3 FY24 10-Q (period ended 6/30/2024) .
  • Q2 FY24 10-Q (period ended 3/31/2024) .
  • Q1 FY24 10-Q (period ended 12/31/2023) .
  • Press release on HemaXellerate Phase 1 planning (Nov 19, 2024) .